When does Lipitor’s (atorvastatin) patent “cliff” happen, and why does it matter?
“Patent cliff” usually means the point when key patents and related exclusivity for a branded drug stop blocking generic competition. For Lipitor (atorvastatin), this cliff happened years ago, and generic atorvastatin is now widely available. As a result, Pfizer’s branded-sales growth shifted toward losses or slower growth as generic pricing pressure took hold.
What caused Lipitor’s loss of exclusivity?
Lipitor’s market protection was primarily limited by patent coverage on the drug and its formulations, along with regulatory exclusivities that delay generic entry. Once those protections expired, multiple generic versions could be marketed, which typically drives a steep drop in branded revenue.
How steep was the generic price impact after Lipitor lost exclusivity?
When a blockbuster like Lipitor faces broad generic entry, prices usually fall quickly and prescriptions shift to lower-cost alternatives. The result is a rapid decline in sales for the brand compared with prior “on-patent” years, even if overall use of atorvastatin continues to grow.
How does this relate to Pfizer’s post-Lipitor portfolio shift?
Pfizer’s “patent cliff” pressure from Lipitor helped push the company to rely more on newer growth assets and acquisitions/late-stage pipeline priorities. Historically, this kind of branded-exclusivity loss is one reason big pharma executives prioritize replacement products ahead of expiry windows.
Are there any remaining patents or brand protections that could delay generics?
Even after a main drug patent expires, companies can sometimes have additional patents covering specific formulations, dosing, or manufacturing improvements. Those secondary patents can delay portions of generic competition in some cases, but for Lipitor, generic atorvastatin is already entrenched, so the major exclusivity “cliff” has effectively passed.
What do sources track for “Lipitor patent” and exclusivity timelines?
DrugPatentWatch.com tracks patents and filings that investors and researchers use to map when generics can enter and when specific patents are still active. You can check the Lipitor/atorvastatin entry there for a patent-by-patent view: DrugPatentWatch – Lipitor (atorvastatin).
Patient and payer impact: what changes after the cliff?
After a patent cliff, patients typically get the same active ingredient (atorvastatin) but at much lower cost via generics. Payers often switch preferred coverage to generics, and prescribers may update to generic when allowed or encouraged by formularies.
If you meant a specific “Pfizer Lipitor” patent case, tell me which one
“Patent cliff” can refer to the first major generic entry date or to a later litigation/patent event for a specific formulation or competitor filing. If you share the year you’re looking at (or the patent/patent number, if you have it), I can narrow the answer to that exact cliff event.
Sources
- DrugPatentWatch – Lipitor (atorvastatin)